Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Sepracor Inc. Q1 2009 Earnings Call Transcript
- Question-and-Answer Session Operator Thank you, Mr. Adams. The floor is now open for questions. Operator Instructions. And our first question is coming from the line of Manoj Garg with Soleil Securities. Please go ahead, your line is open. Manoj Garg - Soleil Group Hey, good morning guys. I’ve...
- Earnings calls 2009-05-04
- Is Pfizer's Sleeping Pill Obsession Running up King Stock?
- Trading in options on King Pharmaceuticals shares reached a four-year frenzy yesterday, Reuters reported, and King shares rose to an 11-month high on rumors that Pfizer may be interested in acquiring it. Pfizer pfollowers know that CEO Jeff Kindler made a lot of noise a few years...
- Blog posts 2008-08-06
Additional Resources
- End of Sepracor-GSK Deal Raises Question in Lunesta Patent Fight
- Here's something that few noticed in Sepracor's Q1 2009 earnings announcement: The company's $155 million marketing deal for insomnia drug Lunesta/Lunivia with GlaxoSmithKline in Europe fell through. The collapse of the deal was predictable. I noted in July 2008 that GSK's subsequent $3.3 billion deal with Actelion...
- Blog posts 2009-06-13
- Isiah Thomas Overdose Indicates Lunesta Has Chink in Armor
- Until now, Sepracor’s Lunesta sleeping pill has enjoyed one advantage over Sanofi-Aventis’s Ambien CR: a superior reputation for safety. The drug is approved by the FDA for long-term use, unlike many of its rivals. And it’s not a benzodiazepine. That reputation changed over the weekend as it...
- Blog posts 2008-10-26
- Sepracor Announces 940 Layoffs; Achieves the Impossible on Lunesta Sales
- Back in August, BNET ragged on Sepracor for implementing a cost-cutting program that drove up its expenses and drove down its revenue. In its Q4 earnings today, the company has turned that all around -- sales are up and expenses are down. The turnaround has come at...
- Blog posts 2009-01-29
- Sepracor Announces Presentation of LUNESTA™ Posters at Associated Professional Sleep Societies Annual Meeting
- MARLBOROUGH, Mass. -- Sepracor Inc. (Nasdaq: SEPR) today announced that data for LUNESTATM brand eszopiclone for the treatment of insomnia were presented at the SLEEP 2006 20th Anniversary Meeting of the Associated Professional Sleep Societies in Salt Lake City. The data included four poster presentations of results from LUNESTA Phase...
- Research articles 2006-06-21
- Sepracor Announces Presentation of LUNESTA™ Data at Associated Professional Sleep Societies 20th Anniversary Meeting
- MARLBOROUGH, Mass. -- Sepracor Inc. (Nasdaq: SEPR) today announced that additional data on LUNESTATM brand eszopiclone for the treatment of insomnia were presented at the SLEEP 2006 20th Anniversary Meeting of the Associated Professional Sleep Societies in Salt Lake City. The data included four oral presentations of results from LUNESTA...
- Research articles 2006-06-23
- Sepracor Has Stopped Advertising Lunesta, But Sales Still Go Up
- Sepracor appears to have almost stopped advertising for sleeping pill Lunesta, and yet sales are still rising. Sepracor spent less than $1 million on ads for the brand in 2009, but Lunesta sales were up 2 percent to $151 million in Q2 2009. by Jim Edwards
- Blog posts 2009-09-15
- Lunesta Data to Be Presented at American Psychiatric Association Annual Meeting
- MARLBOROUGH, Mass. -- Sepracor Inc. (Nasdaq: SEPR) today announced that Phase III/IV clinical data for LUNESTATM brand eszopiclone for the treatment of insomnia will be presented at the American Psychiatric Association APA annual meeting in Atlanta.
- Research articles 2005-05-19
- Sepracor boosts rep ranks for Lunesta
- SEPRACOR IS expanding its sales force by 50% in an attempt to hit 2 million details for its insomnia drug Lunesta eszopiclone, the company said.
- Research articles 2006-03-01
- Top Lunesta marketer leaves Sepracor
- TIM HEALEY, the marketer who helped Sepracor reap first-year Lunesta sales of $465 million with an unparalleled DTC campaign, has jumped ship and joined a small nanoparticle company.
- Research articles 2007-01-01
- Sepracor shifts Lunesta DTC biz
- SEPRACOR HAS shifted its Lunesta DTC advertising business from McCann Erickson to Kaplan Thaler Group.
- Research articles 2008-03-01
- Sepracor Announces Presentation of LUNESTA™ Data at Associated Professional Sleep Societies Annual Meeting
- MARLBOROUGH, Mass. -- Sepracor Inc. (Nasdaq: SEPR) today announced that data for LUNESTATM brand eszopiclone for the treatment of insomnia will be presented at the SLEEP 2006 20th Anniversary Meeting of the Associated Professional Sleep Societies at the Salt Palace Convention Center in Salt Lake City on June 20th and...
- Research articles 2006-06-13
- Sepracor Announces Presentation of LUNESTA™ Data at American Psychiatric Association Annual Meeting
- MARLBOROUGH, Mass. -- Sepracor Inc. (Nasdaq: SEPR) today announced that data from its Phase IIIB/IV studies of LUNESTATM brand eszopiclone for the treatment of insomnia were presented at the annual meeting of the American Psychiatric Association in Toronto.
- Research articles 2006-05-25
- Results of Sepracor's LUNESTA® Next-Day Driving Study in Patients with Primary Insomnia Presented at American College of Neuropsychopharmacology Meeting
- MARLBOROUGH, Mass. -- Sepracor Inc. (Nasdaq: SEPR) today announces the presentation of results from a study of LUNESTA([R]) brand eszopiclone that measured the effects on actual next-morning driving ability and other objective assessments of cognitive and psychomotor function. Results from this randomized, double-blind, placebo-controlled, two-way crossover study in patients with...
- Research articles 2006-12-06
- Sepracor Inc. and Eisai Co. Ltd. Announce Partnership for Development and Commercialization of LUNESTA® in Japan
- * Collaboration is the first partnership for expansion of the LUNESTA([R]) brand eszopiclone franchise outside of U.S.
- Research articles 2007-07-27
- Sepracor Announces Publication of Additional Data from Lunesta® Insomnia-Depression Study in the Journal of Clinical Sleep Medicine
- MARLBOROUGH, Mass. -- Sepracor Inc. (Nasdaq: SEPR) today announced that additional data from its Phase IIIB/IV, 545-patient study of LUNESTA([R])brand eszopiclone in patients with insomnia and co-existing major depressive disorder MDD have been published in the February 2007 edition of the Journal of Clinical Sleep Medicine. This manuscript contains results...
- Research articles 2007-02-21
- Sepracor Announces Publication of LUNESTA™ Insomnia-Depression Study in Biological Psychiatry
- MARLBOROUGH, Mass. -- Sepracor Inc. (Nasdaq: SEPR) today announced that data from its Phase IIIB/IV, 545-patient study of LUNESTATM brand eszopiclone in patients with insomnia and co-existing major depressive disorder MDD have been published. The article is in press and available online in Biological Psychiatry at http://www.sciencedirect.com/science?_ob=IssueURL&_tockey= %23TOC%234982%239999%23999999999%2399999%23FLA%23&_auth=y&view= c&_acct=C000048622&_version=1&_
- Research articles 2006-04-04
- Sepracor Announces Presentation of Lunesta™ Data at American Psychiatric Association Annual Meeting
- MARLBOROUGH, Mass. -- Sepracor Inc. (Nasdaq: SEPR) today announced that data for LUNESTATM brand eszopiclone for the treatment of insomnia will be presented at the annual meeting of the American Psychiatric Association in Toronto on May 23rd and 24th. The posters will be presented in the Toronto Convention Centre, North...
- Research articles 2006-05-22
- Sepracor Tested Sleeping Pill Lunesta on Kids
- The FDA stopped two clinical trials run by Sepracor studying sleeping pill Lunesta in children. The July 4 weekend is traditionally one of those times when companies drop bad news into the media in the hopes that America will be too busy eating and drinking to notice. This year was...
- Blog posts 2009-07-06
- << Previous
- page 1 of 1
- Next >>
